Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

Background: As in many other developed nations, the problem of obesity and type 2 diabetes is acute in Russia. In Russia, the only combination of sibutramine and metformine (Reduxin®Met) is authorized to reduce body mass and prevention development of type 2 diabetes mellitus or its complication. The article presents the results of the observational program “AVRORA”.

Aim: Evaluation of the effectiveness and safety of Reduxin®Met (sibutramine + microcrystalline cellulose + Metformin) in patients with type 2 diabetes and alimentary obesity in routine clinical practice.

Materials & methods: The observational program “AVRORA” was conducted from September 2016 to October 2017 under the auspices of the Endocrinological Scientific Center and the Russian Association of Endocrinologists. The “AVRORA” program was a multicenter, non-interventional study of patients to whom the attending physicians prescribed Reduxin®Met, a set (tablets + capsules), in accordance with the instruction for medical use as part of routine clinical practice. The treated group included patients of both sexes, aged 18–65 years, with an established diagnosis of obesity in combination with type 2 diabetes. The duration of the drug usage was determined by the attending physician and was up to 6 months. Reduxine®Met was prescribed in addition to the existing glucose-lowering therapy, the dose of metformin was adjusted to the patient's needs.

Results: The “AVRORA” study was attended by 259 doctors and 5,812 patients in 240 medical institutions from 12 cities of the Russian Federation. The average age of patients was 46.6 ± 10.5 years, the ratio of male / female -24% / 76%. The decreasing of BMI during 6 months of the therapy amounted to 5.4 ± 2.3 kg / m2 (on average, 15.1 ± 6.4 kg). After 3 months of the therapy 81.6% of patients achieved clinically significant weight loss of 10.6% or more. The average decrease in waist circumference during 6 months of therapy was 13.8 ± 7.4 cm. A decrease of indicators of glycemic control and lipid metabolism right up to the target values was observed.

Conclusions: In “AVRORA” study it was shown that addition of Reduxine®Met (sibutramine+ microcrystalline cellulose+metformine) to the complex therapy of the diabetes in combination with obesity according to approved indications is safe and effective for long-term treatment in regards to weight loss, regulation of lipemic index, glucose profile and quality of life.

obesity, type 2 diabetes, sibutramine, Reduxine, Reduxine®Met, All-Russian observational program “AVRORA”

1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. Available from: http://www.diabetesatlas.org. Accessed 13 Nov 2017.

2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический отчет по данным Федерального регистра сахарного диабета // Сахарный диабет. – 2017. – Т. 20. – №1. – С. 13-41. [Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry. Diabetes mellitus. 2017;20(1):13-41. (In Russ.)] doi: 10.14341/DM8664

3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION) // Сахарный диабет. – 2016. – Т.19. – №2. – С.104-112. [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-112. (In Russ.)] doi: 10.14341/DM2004116-17

4. Lee CMY, Woodward M, Pandeya N, et al. Comparison of relationships between four common anthropometric measures and incident diabetes. Diabetes Res Clin Pract. 2017;132:36 – 44. doi: 10.1016/j.diabres.2017.07.022

5. Riaz H, Khan MS, Siddiqi TJ, et al. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. JAMA Netw Open. 2018;1(7):e183788. doi: 10.1001/jamanetworkopen.2018.3788

6. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metab – Clin Exp. 2018; doi:10.1016/j.metabol.2018.10.011

7. Gancheva S, Jelenik T, Alvares-Hernandes E, Roden M. Interorgan metabolic crosstalk in human insulin resistance. Physiol Rev. 2018; 98:137 – 1415. doi: 10.1152/physrev.00015.2017

8. Hepler C, Gupta RK. The expanding problem of adipose depot remodeling and postnatal adipocyte progenitor recruitment. Mol Cell Endocrinol. 2017;445:95-108. doi: 10.1016/J.MCE.2016.10.011

9. Scherer PE. The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2019;62(2):223-232. doi: 10.1007/s00125-018-4777-x

10. Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes, Obes Metab. 2017;19(9):1295-1305. doi: 10.1111/dom.12971

11. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541–551. doi:10.1016/S0140-6736(17)33102-1

12. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. Cell Metab. 2018;28(4):547-556.e3. doi: 10.1016/j.cmet.2018.07.003

13. Bray GA, Edelstein SL, Crandall JP, et al. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35(4):731-737. doi: 10.2337/dc11-1299

14. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. C Open. 2014;2(3):162-175. doi: 10.9778/cmajo.20130073

15. Malin SK, Kashyap SR. Effects of metformin on weight loss. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323-329. doi: 10.1097/MED.0000000000000095

16. Lv W, Wen J, Li L, et al. The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats. Brain Res. 2012;1444:11-19. doi: 10.1016/j.brainres.2012.01.028

17. Kim H-J, Jin B-Y, Oh M-J, Shin K-H, et al. The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiol Behav. 2016;154:184-190. doi: 10.1016/j.physbeh.2015.11.028

18. Tokubuchi I, Tajiri Y, Iwata S, et al. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. Essop MF, editor. PLoS One. 2017;12(2):e0171293. doi: 10.1371/journal.pone.0171293

19. Fujita K, Iwama H, Oura K, et al. Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. Int J Mol Med. 2016;38(4):1135-1140. doi: 10.3892/ijmm.2016.2729

20. Jing Y, Wu F, Li D, et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256-264. doi: 10.1016/j.mce.2017.09.025

21. Biondo LA, Batatinha HA, Souza CO, et al. Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue. Front Pharmacol. 2018;9:452. doi: 10.3389/fphar.2018.00452

22. Villarroya F, Cereijo R, Gavaldà-Navarro A, et al. Inflammation of brown/beige adipose tissues in obesity and metabolic disease. J Intern Med. 2018;284(5):492-504. doi: 10.1111/joim.12803

23. Breining P, Jensen JB, Sundelin EI, et al. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes, Obes Metab. 2018;20(9):2264-2273. doi: 10.1111/dom.13362

24. Gagnon J, Sheppard E, Anini Y. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes, Obes Metab. 2013;15(3):276-279. doi: 10.1111/dom.12021

25. Bahne E, Sun EWL, Young RL, et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight. 2018;3(23). doi: 10.1172/jci.insight.93936

26. Bahne E, Hansen M, Brønden A, et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabetes, Obes Metab. 2016;18(10):955-961. doi: 10.1111/dom.12697

27. Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919-1929. doi: 10.1038/s41591-018-0222-4

28. Романцова Т.И. Сибутрамин: эффективность и безопасность применения в рутинной клинической практике // Ожирение и метаболизм. – 2015. – Т. 12. – №3. – C. 18-24. [Romantsova TI. Sibutramine: efficacy and safety of prescribing in routine clinical practice. Obesity and metabolism. 2015;12(3):18-24. (In Russ.)] doi: 10.14341/omet2015318-24

29. Аметов А. С. Отчет о программе ВЕСНА. Эффективное лечение ожирения-путь борьбы с эпидемией diabetes mellitus //Эндокринология: Новости. Мнения. Обучение. – 2013. – №2. – С. 12-16. [Ametov AS. Report about the VESNA program. Effective treatment of obesity – the way to combat the epidemic of diabetes mellitus. Èndokrinologiâ. Novosti, mneniâ, obučenie. 2013;(2):12-16. (In Russ.)].

30. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера» // Ожирение и метаболизм. – 2016. – Т. 13. – №1. – C. 36-44. [Dedov II, Mel’nichenko GA, Romantsova TI. The strategy of obesity management: the results of All-Russian observational program “Primavera”. Obesity and metabolism. 2016;13(1):36-44. (In Russ.)] doi: 10.14341/omet2016136-44

31. Абдулкадирова Ф. Р., Покровская Р. А. Роль липотоксичности в достижении гликемического контроля у больных сахарным диабетом 2 типа и ожирением // Эндокринология: Новости. Мнения. Обучение. – 2013. – №3. – C. 96. [Abdulkadirova F.R., Pokrovskaya R.A. Role of the lipotoxicity in glycemic control achieving. Èndokrinologiâ. Novosti, mneniâ, obučenie. 2013;3:96. (In Russ.)]

32. Аметов А.С., Тертычная Е.А. Глюколипотоксичность в дебюте сахарного диабета2-го типа. Лечение и профилактика. – 2014. – Т. 3. – №11. – C. 32-35. [Ametov AS, Tertychnaya EA. The glucolipotoxicity at the debut of diabetes mellitus type II. Lečenie i profilaktika.2014;3(11):32-35. (In Russ.)]

33. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591-601. doi: 10.1016/j.cmet.2016.02.005

34. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск // Сахарный диабет. – 2017. – Т. 20. – №1S. – C. 1-121. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus. 2017;20(1S):1-121. (In Russ.)] doi: 10.14341/DM20171S8